ALPHAEON agrees to bring Zelegent's office-based Elevoplasty technology to sleep specialists

ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Zelegent, Inc. jointly announced today that the two companies have entered into an exclusive worldwide agreement to bring Zelegent's office-based Elevoplasty technology to board certified sleep specialists. Under the terms of the agreement, which includes product development and commercialization, ALPHAEON became the lead investor in Zelegent's Series A Financing. The amount of the investment was not disclosed.

"We are pleased to gain exclusive worldwide commercialization rights to Zelegent's office-based sleep technology, Elevo™, which may become the simplest and most effective way for patients to find relief from snoring without the drawbacks of today's available therapies," said Bart Bandy, President of ALPHAEON Wellness. "This investment represents our first step into the Ear, Nose, and Throat (ENT) specialty."

"According to the American Academy of Otolarynology, forty-five percent of normal adults snore at least occasionally and 25 percent are habitual snorers," said Dr. Krespi, Chairman of the Board of Zelegent, and Director of the Center for Sleep Disorders, and the NYHNI Professor of Clinical Otolaryngology, Columbia University. "As a physician who deals directly with the impact on snorers and resulting strained relationships, I'm very excited at the prospect of providing a simple, office-based minimally-invasive procedure that will bring relief to millions of people."

"ALPHAEON's success and reach with medical devices used in self-pay procedures, and its social commerce platform ShoutMD®, make it an ideal partner to bring Elevo™ to physicians and patients," said Alexander K. Arrow, MD, Chief Executive Officer of Zelegent. "We believe this agreement will make Elevoplasty available to millions of patients who seek relief from the health and social consequences of snoring. "

The Zelegent Elevo and the Elevoplasty kit are investigational devices only and are not yet for sale in the United States.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare